+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07087964

Using PET Scans and Laboratory Tests to Improve Risk Assessment and Treatment in Newly Diagnosed Multiple Myeloma Patients

Led by Universiteit Antwerpen · Updated on 2025-07-28

120

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating newly diagnosed multiple myeloma patients who are undergoing standard of care treatment including induction chemotherapy, autologous stem cell transplant ASCT, and lenalidomide maintenance therapy. The study aims to improve prediction of progression free survival by combining two techniques to detect minimal residual disease MRD. It also seeks to better classify patients by risk factors for early relapse, potentially leading to more personalized treatments in the future. Participants receive a whole-body FDG PETLDCT scan and a bone marrow sample for whole exome sequencing before starting induction chemotherapy. Those achieving at least a very good partial response after induction and ASCT will have repeated scans and MRD testing before starting maintenance therapy, after one year, and after two years of maintenance. Patients not reaching this response will still have follow-up during maintenance but without repeated scans or MRD testing. If relapse occurs, an additional bone marrow sample will be taken. Throughout maintenance therapy, participants are followed at least every three months to monitor treatment response or relapse using routine lab tests. The study measures MRD with next generation flow cytometry and evaluates risk stratification using whole exome sequencing and radiomics. The total follow-up includes up to two years of maintenance therapy or until progression, death, or study end, with ongoing assessments to better understand disease status and patient outcomes.

CONDITIONS

Brief Title

Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients

Research Team

S

Sofie De Rechter

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here